Current causes of death in systemic lupus erythematosus in Europe,2000—2004: relation to disease activity and damage accrual

Abstract

Current therapeutic and diagnostic resources have turned systemic lupus erythematosus (SLE) into a chronic disease by reducing mortality rates. The exact contribution of disease activity and disease related damage to mortality is not well studied. The aim of this study was to describe the current causes of death (COD) in a multinational European cohort of patients with SLE in relation to quantified measures of disease activity and damage. Prospective five-year observational study of case fatalities in SLE patients at 12 European centres was performed. Demographics, disease manifestations, interventions and quantified disease activity (by ECLAM and SLEDAI) and damage (by SLICC-DI) at the time of death were related to the various COD. Ninety-one case fatalities (89% females) occurred after median disease duration of 10.2 years (range 0.2—40) corresponding to a annual case fatality of one for each of the participating cohorts. Cumulative mortality correlated linearly with disease duration with nearly 10% of fatalities occurring in the first year and 40% after more than 10 years of disease. Death occurred during SLE remission in one third of cases. In the remaining cases a mixture of disease activity (median ECLAM 5.5, median SLEDAI 15) and accrued damage (median SLICC-DI 5.0) with opposing relationships to disease duration contributed to death. Infections and cardiovascular events were the most frequent COD in both early and late fatalities with no gender differences for type of COD, disease activity, damage or comorbidity. In Europe, case fatalities have become uncommon events in dedicated SLE cohorts. The bimodal mortality curve has flattened out and deaths now occur evenly throughout the disease course with infectious and cardiovascular complications as the main direct COD in both early and late fatalities. Accrued damage supplants disease activity over time as the main SLE specific contributor to death over time. Lupus (2007) 16, 309—317.

Keywords

cause of death damage disease activity systemic lupus erythematosus Europe

Get full access to this article

View all access options for this article.

References

Urowitz MB , Gladman DD How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology (Oxford) 2000; 39: 238—244.

Gladman DD , Urowitz MB Prognosis, mortality, and morbidity in systemic lupus erythematosus. In Wallace DJ , Hahn BH eds. Dubois' lupus erythematosus, 6th edition. Lippincott Williams & Wilkins , 2002: 1255—1273.

Bjornadal L. , Yin L. , Granath F. , Klareskog L. , Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964—95. J Rheumatol 2004; 31: 713—719.

Stahl-Hallengren C. , Jonsen A. , Nived O. , Sturfelt G. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 2000; 27: 685—691.

Abu-Shakra M. , Urowitz MB , Gladman DD , Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995; 22: 1259—1264.

Urowitz MB , Bookman AA , Koehler BE , Gordon DA , Smythe HA , Ogryzlo MA The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221—225.

Helve T. Prevalence and mortality rates of systemic lupus erythematosus and causes of death in SLE patients in Finland. Scand J Rheumatol 1985; 14: 43—46.

Halberg D. Survival and causes of death in patients with systemic lupus erythematosus . Clin Rheumatol 1991; 10: 367—368.

Cohen MG , Li EK Mortality in systemic lupus erythematosus: active disease is the most important factor. Aust N Z J Med 1992; 22: 5—8.

10.

Nossent JC Course and prognostic value of Systemic Lupus Erythematosus Disease Activity Index in black Caribbean patients. Semin Arthritis Rheum 1993; 23: 16—21.

11.

Alarcon GS , McGwin G. Jr , Bastian HM et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum 2001; 45: 191—202.

12.

Jacobsen S. , Petersen J. , Ullman S. et al. Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand J Rheumatol 1999; 28: 75—80.

13.

Cervera R. , Khamashta MA , Font J. et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82: 299—308.

14.

Pons-Estel BA , Catoggio LJ , Cardiel MH et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics”. Medicine (Baltimore) 2004; 83: 1—17.

15.

Swaak AJ , van den Brink HG , Smeenk RJ et al. Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology (Oxford) 1999; 38: 953—958.

16.

Swaak AJ , van den Brink HG , Smeenk RJ et al. Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation. Lupus 2001; 10: 51—58.

17.

Swaak AJ , van de BH , Smeenk RJ et al. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford) 2001; 40: 89—94.

18.

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271—1277.

19.

Hochberg MC Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

20.

Reveille JD , Bartolucci A. , Alarcon GS Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990; 33: 37—48.

21.

Calvo-Alen J. , Reveille JD , Rodriguez-Valverde V. et al. Clinical, immunogenetic and outcome features of Hispanic systemic lupus erythematosus patients of different ethnic ancestry. Lupus 2003; 12: 377—385.

22.

Koh ET , Seow A. , Leong KH , Chng HH SLE mortality in an oriental population. Lupus 1997; 6: 27—31.

23.

Costenbader KH , Liang MH Arthritis Res Ther 2003; 5: 178—179.

24.

Bruce IN `Not only . . . but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 1492—1502.

25.

Haque S. , Bruce IN Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat Clin Pract Cardiovasc Med 2005 ; 2: 423—430.

26.

Jimenez S. , Cervera R. , Font J. , Ingelmo M. The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol 2003; 25: 3—12.

27.

Nossent HC Systemic lupus erythematosus in the Arctic region of Norway. J Rheumatol 2001; 28: 539—546.